logo

Canadian Journal of Gastroenterology and Hepatology

Canadian Journal of Gastroenterology and Hepatology / 2019 / Article / Tab 2

Research Article

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

Table 2

Efficacy total, by primary regimen including on schedule/discont, by rescue regimen, by GT, and by fibrosis.
 ITT, n (%)mITT, n (%)
 completed primary therapydiscontinued primary therapycompleted primary therapydiscontinued primary therapy
by primary regimen    
OBV/PTV/r+DSV ± RBV3/4 (75%)10/11 (91%)3/4 (75%)10/10 (100%)
LDV/SOF ± RBV4/7 (57%)04/6 (67%)0
other SOF based5/5 (100%)05/5 (100%)0
ASV+DCV2/3 (67%)1/1 (100%)2/3 (67%)1/1 (100%)
by rescue regimen    
OBV/PTV/r ± DSV ± RBV3/4 (75%)1/1 (100%)3/4 (75%)1/1 (100%)
LDV/SOF ± RBV6/8 (75%)10/11 (91%)6/8 (75%)10/10 (100%)
GZR/EBR2/3 (67%)02/2 (100%)0
SOF+DCV ± RBV2/3 (67%)02/3 (67%)0
by genotype    
1b9/12 (75%)10/11 (91%)9/12 (75%)10/10 (100%)
32/3 (67%)02/3 (67%)0
43/4 (75%)1/1 (100%)3/3 (100%)1/1 (100%)
by fibrosis    
non-cirrhotics6/6 (100%)3/3 (100%)6/6 (100%)3/3 (100%)
cirrhotics8/13 (62%)8/9 (89%)8/12 (67%)8/8 (100%)
GT: genotype; ITT: intent-to-treat; mITT: modified intent-to-treat; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir; GZR: grazoprevir; EBR: elbasvir.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.